DBV Technologies Announces Details for Upcoming General Meeting

DBV Technologies, a late-stage biopharmaceutical company, is set to hold its Combined General Meeting on June 3, 2026. Scheduled for 10:00 a.m. CEST, the meeting will take place at the company's headquarters in Châtillon, France. Shareholders were informed about the meeting through a notice published on April 29, 2026, in the French Bulletin des Annonces Légales Obligatoires (BALO).

Key documents and preparatory materials for the meeting have been made accessible on the company's website. Shareholders have until May 29, 2026, to request these documents via email. The meeting will be streamed live online, with a recorded version available within seven business days post-meeting.

DBV Technologies focuses on developing treatments for food allergies utilizing its VIASKIN® patch technology, particularly targeting peanut allergies in young children.